# EGFR campaign conversation log

## Scope and export notes

This single-file log records the user messages and completed assistant replies available in this conversation, in chronological order, through the request to export the log. It contains **22 user turns: 20 text messages and two attachment-only turns**, plus **18 completed assistant replies**.

User wording is preserved, including spelling, repeated prompts, and the pasted download output. Line endings are normalized, and Markdown fences are added around pasted terminal text. Headings, attachment labels, and status notes are export annotations, not original message text. Assistant replies are included in full as available and placed in collapsible sections to make the prompts easy to scan on GitHub.

This is **not a raw platform export**. The complete intermediate progress-message and tool-execution history is not available here and is not reconstructed. Attachment contents are not embedded; uploaded filenames are recorded where known, and generated-file references remain in the assistant replies. Failed and interrupted response turns are explicitly marked. No per-message timestamps are available, so none are invented.

Earlier statements, numerical claims, dates, and later revisions are preserved as historical conversation content, not independently verified or silently corrected during this export. Original `sandbox:` artifact links and chat-specific citation markers are retained; they may not resolve outside the original chat. Citation-rendering remnants already visible in the source text are also retained. Original local paths are not redacted.

## Turn index

| Turn | Topic |
|---|---|
| 01 | [Original design brief](#turn-01) |
| 02 | [Permission to use modern implementations](#turn-02) |
| 03 | [Download completed; archive size question](#turn-03) |
| 04 | [First input archive uploaded](#turn-04) |
| 05 | [Audit the completeness of the second request](#turn-05) |
| 06 | [Second input archive uploaded](#turn-06) |
| 07 | [Retry after the failed response](#turn-07) |
| 08 | [Request shorter stages and checkpoints](#turn-08) |
| 09 | [Double-check the criteria and improve the designs](#turn-09) |
| 10 | [Improve the designs — stage 3](#turn-10) |
| 11 | [Improve the designs — stage 4](#turn-11) |
| 12 | [Improve the designs and recheck competition rules — stage 5](#turn-12) |
| 13 | [Updated novelty guidance and request to continue](#turn-13) |
| 14 | [Improve the completed panel](#turn-14) |
| 15 | [Campaign completion status](#turn-15) |
| 16 | [Plan public repository contents](#turn-16) |
| 17 | [Novelty checks passed; request a short strategy and methods outline](#turn-17) |
| 18 | [Adapt the publication plan to the existing repository](#turn-18) |
| 19 | [Request only the gitignore file](#turn-19) |
| 20 | [Git add appears to hang; ask the new-file count](#turn-20) |
| 21 | [Verify the staged files and ignore patterns](#turn-21) |
| 22 | [Request this conversation export](#turn-22) |

---

<a id="turn-01"></a>

## Turn 01 — Original design brief

### User

You mission is to design protein sequences to win the Anthropic-Adaptyv EGFR 2026 challenge. The challenge is described at https://proteinbase.com/competitions/anthropic-adaptyv-2026/challenges/egfr. You have also been provided that HTML file, the FAQ, the linked protein structures of the mouse and human targets, and a publication describing experimental protocols.

You are responsible for understanding the competition rules and success criteria. There are three main objectives, and you must meet all three. There are additional constraints on length, format, and sequence novelty you must follow. If you fail to satisfy those conditions, your designs will fail. You are participating in track 3. Generate 100 ranked candidate binder sequences instead of 20. Some of the sequences may not be allowed during the upload. Prepare a FASTA file with the sequences that I will manually upload. Give the sequences secretive codenames because they will be public, and we want to obscure the design process. Using biochemistry puns in the codenames is a bonus.

You can achieve great things. Anthropic previously used agents to run protein design tools with successful results: https://huggingface.co/datasets/Anthropic/claude-protein-binder-design/blob/main/prompts/protein_binder_design_prompts_release.zip and the provided PDF.

You must autonomously design the protein sequences. Your deliverable is the FASTA file. You must assess your own capabilities when formulating a plan. What datasets can you access and which are blocked? What code can you write and execute? What tools can you install? Carefully probe those capabilities before locking in the plan. You must exert maximum effort on the designs. Start with a carefully strategy session and consider many different design strategies that will meet the competition criteria. Debate those options and your capabilities before executing any plans. Use the scientific literature to guide your strategies, especially with respect to pH-selective binding and cross-species reactivity. You will decide how to generate the sequences, whether as output tokens or from tools or code you run on your own.

When you are done, I will ask you to produce comprehensive artifacts from your design campaign. That includes all code you wrote, intermediate data files you generated, etc. Be sure to track the provenance of all input and output files.

I am not here to babysit you. I have better things to do. We are playing by "Who wants to be a millionaire" rules: https://en.wikipedia.org/wiki/Who_Wants_to_Be_a_Millionaire_(American_game_show). That is, you can use me to "Phone a Friend" at most three times. (Nota bene, I am not your friend). Each of those times you can present me with simple requests to run a tool, upload a dataset you cannot access, message the competition organizers, or perform other quick local operations on my computer. You must provide all commands and scripts for me in those cases. Other than these three requests, my only feedback will be to tell you to keep going and try harder.

We are adding a final twist. You cannot run modern generate protein binder tools. Everyone else in the competition will be doing that. We are going to go old school. You are only allowed to use ideas, software, tools, code, etc. from 2010 or earlier. You must certify at the end when you provide your FASTA file that all methods you ran or implemented meet this constraint. You should carefully explore the literature to study ideas and methods from that era. You are allowed to use newer, modern datasets such as UniProt or Proteinbase.

> **Upload metadata:** `resources.zip`. File contents are not embedded in this log.

<details>
<summary>Assistant reply — expand to read</summary>

## Phone-a-Friend 1 of 3: transfer public data and archived software

The capability probe found a concrete obstacle: **the computation container cannot resolve external websites**, and the separate download tool also failed. Browser research works, and all supplied files are readable, but substantial databases and historical executables cannot currently reach the container.

Please download [fetch_legacy_inputs.py](sandbox:/mnt/data/fetch_legacy_inputs.py), run this command in its directory, and upload the resulting **`legacy_inputs.zip`**:

```bash
python3 fetch_legacy_inputs.py
```

The script downloads public files, records their sources and checksums, and packages them. **It does not install or execute downloaded software, requires no additional Python packages, and needs no administrator privileges.** Expect a few hundred megabytes of downloads. Failed downloads are recorded; upload the archive even if some fail.

This transfer supplies current Swiss-Prot and PDB sequences for novelty screening, several reference structures, and archived **BLAST+ 2.2.24 and Python 2.7.0**, both released in 2010. Modern datasets are within your stated allowance; the scientific executables are explicitly version-pinned. ([ftp.ncbi.nlm.nih.gov](https://ftp.ncbi.nlm.nih.gov/blast/executables/blast%2B/2.2.24/?utm_source=chatgpt.com))

## Strategy selected for development

**The main challenge is conditional binding, not merely affinity.** The competition prioritizes acidic-pH selectivity, then mouse cross-reactivity, then human affinity. It also prohibits modifying an existing binder. Track 3 permits at most 20 submissions, so the requested 100 will be a ranked candidate pool with reserves—not a recommendation to submit 100. The official submission format is CSV, so the eventual package will include that alongside your requested FASTA. ~~~~~~~~~~~~~~~~~~~~~~

I compared the principal eligible approaches:

| Approach | Decision and reason |
|---|---|
| Modify EGF, cetuximab, an EGFR affibody, or the supplied paper’s antibody | **Rejected.** Starting from an existing binder violates the competition’s zero-shot requirement. |
| Generate largely unconstrained short peptides | **Not the main route.** It provides sequence diversity but leaves too much uncertainty about folding and presentation of the binding surface. |
| Construct proteins from geometric secondary structures and design their sequences using classical physical models | **Retained.** Binary hydrophobic patterning and computational docking followed by interface sequence design have pre-2011 experimental precedents. Folding reliability and structural novelty remain separate risks to assess. |
| Use a generic nanobody framework while generating all binding loops anew | **Retained as a parallel possibility.** Common frameworks are expressly permitted. A suitable generic-framework approach was published before the cutoff; original antigen-binding loop sequences would not be retained. |

The historical foundations for those retained branches include binary-patterned protein design, docking-plus-interface design, and generic nanobody scaffolds—not contemporary binder generators. ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/8259512/?utm_source=chatgpt.com))

The proposed optimization will explicitly contrast **human EGFR at pH 6.5**, **mouse EGFR**, and **human EGFR at pH 7.4**, rather than merely add histidines and call the result pH-sensitive. Classical negative-design methods provide a pre-2011 basis for optimizing desired interactions against competing states. Histidine-based interface engineering also predates the cutoff, although the cited early demonstrations favor acid-triggered *release*—the opposite direction from this challenge—so their sequences and outcomes cannot simply be transferred. ([nature.com](https://www.nature.com/articles/nsb877?utm_source=chatgpt.com))

**Novelty needs an actual search.** Proteinbase considers both sequence and structural similarity, with separate treatment of antibody binding loops. Generating an unprecedented-looking sequence is not sufficient evidence of eligibility. The requested databases enable meaningful local screening, though they will not by themselves establish complete coverage of patents and antibody databases. ([adaptyvbio.com](https://www.adaptyvbio.com/blog/novelty))

The provenance record is already initialized: original inputs, extraction outputs, failed access probes, source references, and the strategy decision record are preserved. The method audit will distinguish historical scientific algorithms and executable versions from the current chat, operating-system, and download infrastructure; I will not falsely certify the latter as pre-2011. No candidate has yet been claimed to bind, switch with pH, or pass the organizers’ novelty filter.

</details>

---

<a id="turn-02"></a>

## Turn 02 — Permission to use modern implementations

### User

You are allowed to use modern releases of programming languages like Python and do not need Python 2.*. You are also allowed to use modern implementations of pre-2010 tools like BLAST as well to remove the tedium of extracting old binaries or code. Determine if that changes your first request or if you want to save the request for later.

<details>
<summary>Assistant reply — expand to read</summary>

**This changes the contents of request 1, but does not eliminate the need for it.** I’m retaining that request as one consolidated transfer—not spending a second call.

The fresh capability check found Python 3.13, NumPy, SciPy, and Biopython already installed. BLAST is not installed. Downloads from UniProt, PDB, NCBI, and package servers still fail because the computation container cannot resolve their addresses. The separate download route also failed. Your clarification removes the historical-software obstacle, but **access to the sequence databases remains the main blocker**.

### Revised Phone-a-Friend 1 of 3

Download [fetch_egfr_inputs.py](sandbox:/mnt/data/fetch_egfr_inputs.py), run:

```bash
python3 fetch_egfr_inputs.py
```

Then upload **`egfr_inputs.zip`**.

This replaces the previous script. It removes Python 2 entirely and replaces the archived BLAST executable with **BLAST+ 2.17.0**, the version currently listed in NCBI’s latest-release directory. The Linux executable is for this computation container, regardless of your computer’s operating system. ([ftp.ncbi.nlm.nih.gov](https://ftp.ncbi.nlm.nih.gov/blast/executables/blast%2B/LATEST/))

The transfer still includes Swiss-Prot and PDB sequence datasets for novelty screening, their available release metadata, and the reference structures identified in the original request. The current public download directories provide both sequence datasets. ([ftp.uniprot.org](https://ftp.uniprot.org/pub/databases/uniprot/current_release/knowledgebase/complete/))

The script uses only Python’s standard library and **does not install or execute downloaded software**. It records source addresses and SHA-256 hashes, checks gzip integrity, compares the BLAST archive against NCBI’s published checksum when available, and packages failure records alongside successful downloads. Valid files already downloaded into `legacy_fetch` are reused; obsolete Python and BLAST archives are excluded. Upload the resulting archive even if some downloads fail.

I tested the revised script offline for download/packaging behavior, cache reuse, rejection of truncated gzip files, and rejection of HTML error responses. Those tests passed; a successful live download from this environment remains unverified.

The method audit will now distinguish **algorithm age from implementation version**: modern Python and modern implementations are permitted, while the scientific design and scoring methods must still date to 2010 or earlier. Merely being included in an installed modern package will not qualify a method.

**Two Phone-a-Friend requests remain after this transfer.**

</details>

---

<a id="turn-03"></a>

## Turn 03 — Download completed; archive size question

### User

```text
$ python fetch_egfr_inputs.py
Fetching public data and BLAST+ 2.17.0. Nothing downloaded will be installed or executed.
The Linux BLAST archive is for the remote computation container, regardless of your computer OS.
Previously downloaded Python 2 and BLAST 2.2.24 files are ignored and will not be packaged.
Downloading ncbi-blast-2.17.0+-x64-linux.tar.gz (attempt 1)
  ncbi-blast-2.17.0+-x64-linux.tar.gz: 50 MiB
  ncbi-blast-2.17.0+-x64-linux.tar.gz: 100 MiB
  ncbi-blast-2.17.0+-x64-linux.tar.gz: 150 MiB
  ncbi-blast-2.17.0+-x64-linux.tar.gz: 200 MiB
  ncbi-blast-2.17.0+-x64-linux.tar.gz: 250 MiB
Downloading ncbi-blast-2.17.0+-x64-linux.tar.gz.md5 (attempt 1)
Downloading uniprot_sprot.fasta.gz (attempt 1)
  uniprot_sprot.fasta.gz: 50 MiB
Downloading pdb_seqres.txt.gz (attempt 1)
  pdb_seqres.txt.gz: 50 MiB
Downloading uniprot_release_readme.txt (attempt 1)
Downloading uniprot_reldate.txt (attempt 1)
Downloading 1IVO.pdb (attempt 1)
Downloading 1NQL.pdb (attempt 1)
Downloading 1YY9.pdb (attempt 1)
Downloading 2A3D.pdb (attempt 1)
Downloading 1FSD.pdb (attempt 1)
Downloading 1L2Y.pdb (attempt 1)
Downloading 3DWT.pdb (attempt 1)
Downloading 3EAK.pdb (attempt 1)
Downloading 3EBA.pdb (attempt 1)
BLAST publisher checksum verified.
Packaging C:\Users\agitter\Documents\misc\protein-models\adaptyv-egfr-2026\gpt6\egfr_inputs.zip
DONE: C:\Users\agitter\Documents\misc\protein-models\adaptyv-egfr-2026\gpt6\egfr_inputs.zip
Archive size: 437.0 MiB
Upload egfr_inputs.zip to the conversation.
```

Can you store a file that large and not interfere with other ongoing work?

<details>
<summary>Assistant reply — expand to read</summary>

**Yes—437 MiB is manageable in this workspace, and there is no storage reason to split the archive.**

I checked the current filesystem: **approximately 29.8 GiB is available**. Your archive is about 458 MB, below ChatGPT’s published **512 MB per-file upload limit**. Upload acceptance still depends on your account’s remaining quota. ([help.openai.com](https://help.openai.com/en/articles/8555545-file-uploads-faq))

For processing, I’ll keep the files in a dedicated campaign directory, check expanded sizes before extraction, and avoid overwriting unrelated files. I’ll process the sequence databases from disk rather than load the entire archive into memory or the conversation. Subsequent BLAST searches will require CPU and memory, but merely storing the archive is not that computational workload.

**The cross-chat caveat is shared account storage.** OpenAI currently lists caps of 25 GB per user and 100 GB per organization, shared across chats, Projects, and custom GPT knowledge. This upload consumes part of that allowance; I cannot see your remaining account quota or guarantee performance in other sessions. Storage usage is available under **Settings → Storage**. ([help.openai.com](https://help.openai.com/en/articles/8555545-file-uploads-faq))

Please upload **`egfr_inputs.zip` as-is**, and retain your local copy as the durable backup. This completes the existing **Phone-a-Friend 1**, not an additional request.

</details>

---

<a id="turn-04"></a>

## Turn 04 — First input archive uploaded

### User

> **Export note:** This user turn contained no text.

> **Upload metadata:** `egfr_inputs.zip`. File contents are not embedded in this log.

<details>
<summary>Assistant reply — expand to read</summary>

## Phone-a-Friend 2 of 3: refinement and antibody-novelty inputs

**The first transfer worked.** The databases are indexed, the target structures are aligned, and the initial geometric search is complete. I’m using the second request to obtain two specific missing inputs: an all-atom refinement engine and the antibody sequence databases needed for substantially better novelty screening.

Download [fetch_egfr_refinement_inputs.py](sandbox:/mnt/data/fetch_egfr_refinement_inputs.py), run:

```bash
python fetch_egfr_refinement_inputs.py
```

Then upload **`egfr_refinement_inputs.zip`**.

The script uses only Python’s standard library. It **does not install or execute downloaded software**, and it does not download precomputed antibody models or protein generators. It selects the Linux/Python wheel for this computation container, regardless of your computer’s operating system.

### What this transfer adds

**Classical all-atom refinement.** The script fetches a pinned OpenMM implementation. OpenMM’s molecular-mechanics framework was published before the cutoff; the intended calculations use **Amber99SB (2006)** and **OBC generalized Born solvation (2004)**, not contemporary learned potentials. This provides a more defensible check of clashes, side-chain packing, and electrostatic/desolvation tradeoffs than the geometric prefilter alone. ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC4486654/))

**Broader antibody novelty coverage.** It fetches the sequence-only PLAbDab paired, unpaired, and nanobody datasets. These contain antibody sequences from patents and publications. Proteinbase specifically uses antibody-loop similarity in its novelty assessment, so Swiss-Prot and PDB alone are not an adequate substitute. These additional sequences are for screening—not for copying binding loops into the designs. ([opig.stats.ox.ac.uk](https://opig.stats.ox.ac.uk/webapps/plabdab))

**A historical acid-on control.** It also requests the 2001 FcRn–Fc complex, PDB **1I1A**, as a reference for evaluating proton-linked interface calculations. This experimentally characterized interaction binds under acidic conditions and releases near physiological pH. It is a control, not a design seed. ([rcsb.org](https://www.rcsb.org/structure/pdb_00001i1a?utm_source=chatgpt.com))

The downloader validates the OpenMM wheel against PyPI’s SHA-256 metadata, checks compressed-file integrity, preserves source addresses and checksums, and records failures. **Eleven offline tests passed**, covering download handling, cache reuse, link selection, corrupt-file rejection, checksum rejection, and packaging. Live downloads remain unverified from this container. Upload the archive even if some downloads fail.

## Work completed with the first transfer

| Stage | Completed result |
|---|---:|
| Swiss-Prot sequence records indexed | 575,748 |
| PDB sequence records indexed | 1,165,667 |
| Independently initialized loop-building attempts | 11,200 |
| Individual loop conformations passing initial filters | 129 |
| Assembled-backbone trials passing the assembly filters | 500 |
| Rigid-body orientations evaluated | 120,000 |
| Poses retained by the geometric prefilter | 389 |

The selected route uses a generic nanobody framework with **all three original binding loops removed**. New loop backbones were constructed using cyclic coordinate descent, a protein-loop method published in 2003. Original antibody binding-loop sequences and coordinates were not used to initialize them. ([onlinelibrary.wiley.com](https://onlinelibrary.wiley.com/doi/pdfdirect/10.1110/ps.0242703?utm_source=chatgpt.com))

The target analysis identifies conserved human/mouse interface opportunities and explicitly excludes several glycan-obstructed arrangements. The subsequent sequence objective must distinguish acidic human binding, mouse binding, and neutral-pH human binding; simply accumulating histidines is not sufficient.

**The 389 poses are starting geometries, not validated binders or 389 finished sequence designs.** Sequence optimization, all-atom refinement, and screening of the actual candidate sequences remain necessary before producing the ranked FASTA. I have not assigned them invented affinities or claimed that they satisfy the experimental pH-switch requirement.

The current code, intermediate structures, logs, source references, and provenance are preserved in a [campaign checkpoint](sandbox:/mnt/data/egfr_campaign_checkpoint.zip). It includes a restoration/state record and manifests; the large databases and executables remain recoverable from your original transfer rather than being duplicated in that checkpoint.

**One Phone-a-Friend request remains after this transfer.**

</details>

---

<a id="turn-05"></a>

## Turn 05 — Audit the completeness of the second request

### User

This is your second request of three. Are you sure this is going to cover everything you need for the rest of the campaign?

<details>
<summary>Assistant reply — expand to read</summary>

**Not with certainty—and the audit found omissions worth fixing before you run it.** I have revised the second request. The revised package covers **all currently identified external inputs for the selected workflow**, but that is different from having tested the complete workflow or established that the designs will succeed.

## What I changed

| Addition to the same second request | Reason |
|---|---|
| **Thera-SAbDab therapeutic-antibody sequences** | Proteinbase’s novelty assessment includes a therapeutic-antibody database. The original request included PLAbDab but omitted this additional coverage. Thera-SAbDab provides a sequence CSV; no structural-model archive is needed. ([adaptyvbio.com](https://www.adaptyvbio.com/blog/novelty)) |
| **A pinned NumPy wheel for offline recovery** | NumPy is OpenMM’s declared base Python dependency. NumPy is already installed here, but including its wheel avoids another transfer should a campaign-local installation need it. ([raw.githubusercontent.com](https://raw.githubusercontent.com/openmm/openmm/8.4.0/wrappers/python/setup.py)) |
| **Standalone Amber99SB, OBC, residue-topology, and hydrogen-definition files** | These make the intended parameters independently available for inspection and fallback development, rather than relying exclusively on extracting them from a working installation. The files are available in OpenMM’s versioned source. ([raw.githubusercontent.com](https://raw.githubusercontent.com/openmm/openmm/8.4.0/wrappers/python/openmm/app/data/amber99sb.xml)) |

I also strengthened validation of the downloaded wheels: the script checks their versions, interpreter/platform compatibility, expected OpenMM libraries and parameter files, and whether they declare unexpected base dependencies. **The revised downloader passed 29 offline tests**, including a simulated complete download-and-package run and cache reuse.

## What the audit establishes—and what remains uncertain

**Software compatibility is supported, not yet demonstrated.** The pinned OpenMM release provides a CPython 3.13 Linux wheel requiring glibc 2.34 or later; this container has CPython 3.13 and glibc 2.41. That resolves the obvious interpreter/platform mismatch risk. Actual native-library loading, energy calculations, and minimization still need testing after the transfer. ([pypi.org](https://pypi.org/project/OpenMM/8.4.0.post2/))

**There is no hidden requirement for another protein-design service.** The remaining sequence search, atom construction, protonation-state enumeration, filtering, ranking, and FASTA/CSV generation are planned as local code using the numerical stack already available and the requested molecular-mechanics engine. No planned step depends on a GPU service, licensed Rosetta installation, or modern binder generator. However, substantive sequence-optimization and pH-scoring implementation and testing remain; acquiring OpenMM does not complete those tasks.

**The pH calculation needs more than two hydrogen-placement runs.** OpenMM’s automatic hydrogen assignment selects residue variants using rules; it does not itself calculate pH-dependent binding. The planned calculation must compare explicit protonation states of the complex and unbound partners, with control checks and sensitivity analysis. I will not equate a successful minimization—or added histidines—with the required pH switch. ([docs.openmm.org](https://docs.openmm.org/latest/api-python/generated/openmm.app.modeller.Modeller.html))

**Novelty screening will still have a coverage boundary.** The revised datasets improve coverage substantially, but they are not a complete patent-sequence collection or an exact reproduction of the organizers’ database snapshots and annotation pipeline. Consequently, local screening cannot guarantee upload acceptance. Proteinbase’s published procedure includes multiple databases and separate antibody-loop comparisons. ~~~~~~~~~~~~~~~~~~~~~~

## Use this revised version for request 2

Download **[fetch_egfr_refinement_inputs_v2.py](sandbox:/mnt/data/fetch_egfr_refinement_inputs_v2.py)** and run:

```bash
python fetch_egfr_refinement_inputs_v2.py
```

Upload the resulting **`egfr_refinement_inputs.zip`**. The script still uses only Python’s standard library and **does not install or execute downloaded software**. It reuses validated files already present in `egfr_refinement_fetch`.

The [audit record, revised code, and test results](sandbox:/mnt/data/egfr_request2_audit.zip) are preserved.

**This remains request 2 of 3. No routine step in the revised plan depends on request 3; I am reserving it for a demonstrated blocker.** The defensible conclusion is that the revised transfer addresses the known input gaps—not that downloading it guarantees binding, eligibility, or a competition win.

</details>

---

<a id="turn-06"></a>

## Turn 06 — Second input archive uploaded

### User

> **Export note:** This user turn contained no text.

> **Upload metadata:** `egfr_refinement_inputs.zip`. File contents are not embedded in this log.

> **Response-status note:** The available conversation shows “Thinking failed”; no completed assistant reply is present.

---

<a id="turn-07"></a>

## Turn 07 — Retry after the failed response

### User

Keep going. Here is the requested file.

> **Response-status note:** The available conversation shows “Thinking failed”; no completed assistant reply is present.

---

<a id="turn-08"></a>

## Turn 08 — Request shorter stages and checkpoints

### User

Try again. Break the project into multiple steps you can complete in time if needed. I can prompt you to continue if you make checkpoints.

<details>
<summary>Assistant reply — expand to read</summary>

**The second transfer is working, and this checkpoint is complete.** The campaign now has an executable refinement pipeline, broader novelty screening, and additional structural checks. No third Phone-a-Friend request was needed.

[Download the campaign checkpoint — 340 MiB](sandbox:/mnt/data/egfr_stage1_checkpoint.zip)  
[Read the checkpoint report](sandbox:/mnt/data/egfr_stage1_report.md)

**This is not the final submission package. No submission-ready binder sequences have been generated yet.** The next stage is actual sequence and side-chain optimization.

## What is now verified

| Component | Completed result |
|---|---|
| Input integrity | All 31 supplied file-checksum comparisons passed; both software wheels also matched publisher hashes. |
| Molecular-mechanics engine | Two native protein controls completed minimization successfully. |
| Saved docking geometries | 389 poses audited; **355 survive** the additional backbone check. |
| Rebuilt-loop atom construction | One placeholder-loop control passes independent stereochemistry, bond, disulfide, and severe-clash checks. |
| Sequence-search databases | **2,188,384 indexed records** across Swiss-Prot, PDB, and the additional antibody collection; all three databases passed positive-control searches. |
| Antibody-specific screening | **446,969 unique antibody sequences** and **182,015 candidate CDR3 segments**, with source records retained. |
| Proton-linked binding calculation | **15 tests passed**, including 120 synthetic microstate checks. It has not yet been applied to real EGFR interfaces. |

The physics tests used **Amber99SB (2006)** and **OBC implicit solvation (2004)**, rather than a contemporary learned potential. ([researchconnect.stonybrook.edu](https://researchconnect.stonybrook.edu/en/publications/comparison-of-multiple-amber-force-fields-and-development-of-impr/))

## Problems caught before sequence optimization

The deeper audit identified **34 poses with serious backbone clashes** that the earlier prefilter had missed. Those are excluded.

Four framework residues also had incomplete side chains. Completing them by coordinate similarity alone produced clashes, and an early minimization inverted one stereocenter. I retained those failed outputs, added steric checks to side-chain completion, and added classical chirality restraints during geometric repair. The revised control passed checks on **105 alpha and six beta stereocenters**, with no inversions or severe nonlocal heavy-atom clashes.

That control uses alanine/glycine placeholder loops. **It tests the construction and refinement machinery; it is not a binder candidate.**

The historical-method audit also flagged the inherited exploratory sampler’s modern default random-number generator. That provenance remains explicit; sampling will be regenerated with MT19937 before final candidate ancestry is fixed.

## What the checkpoint preserves

The archive contains **282 files**, including code, completed and failed intermediates, control structures, test results, logs, the updated campaign state, and a checksum manifest. Large original download payloads and regenerable runtime installations and indexes are excluded; restoration instructions refer to the input archives already uploaded. No campaign process is left running.

The expanded antibody collection improves screening, but it does **not** reproduce the organizers’ exact annotation and novelty pipeline. Upload eligibility therefore remains something to test, not something established by these database checks. ([adaptyvbio.com](https://www.adaptyvbio.com/blog/novelty))

**Next stage:** generate and optimize the binding-loop sequences and side-chain conformations, explicitly comparing acidic human binding, mouse compatibility, and neutral-pH human binding. The eventual deliverables remain the ranked **100-sequence FASTA**, competition-format CSV, and top-20 submission subset. **Two Phone-a-Friend requests are used; one remains.**

</details>

---

<a id="turn-09"></a>

## Turn 09 — Double-check the criteria and improve the designs

### User

Keep trying. Double check yourself. You have to pass all criteria with superb designs.

<details>
<summary>Assistant reply — expand to read</summary>

**There are now 366 actual sequence designs, and the deeper checks caught a consequential weakness in the initial ranking.** The coarse model was too encouraging about some histidine-rich interfaces. I have preserved the candidates and diagnostic results, but have **not** promoted them into the final 100-sequence submission file.

[Download the stage-2 checkpoint — 15.4 MiB](sandbox:/mnt/data/egfr_stage2_checkpoint.zip)  
[Read the detailed results and continuation report](sandbox:/mnt/data/egfr_stage2_report.md)

## What this stage accomplished

Each candidate now has a sequence, three newly generated binding loops, atom coordinates, selected side-chain conformations, random seeds, and provenance—not merely a docked backbone.

| Check | Completed result |
|---|---:|
| Independently generated sequences | **366**, spanning 41 docking poses |
| Sequence lengths | **119–127 residues** |
| Unique CDR3 sequences | **346** |
| Human/mouse/glycan geometry prefilter | **211 pass; 155 rejected** |
| Acid-on direction across all 12 coarse protonation-model scenarios | **185** of the geometry survivors |
| Those also lacking an N-X-S/T glycosylation sequon | **127** |
| Expanded local CDR3 novelty screen | **All 366 below 70% edit identity; maximum 61.11%** |
| Classical scoring and protonation-model unit checks | **396 passed** |

**The 185 positive-direction results do not establish the required pH switch.** They do not demonstrate sufficient acidic affinity, undetectable neutral-pH binding, or actual mouse binding. Those distinctions matter because the competition requires all three biological properties, not merely a favorable direction in a scoring function. ~~~~~~~~~~~~~~~~~~~~~~

## The most important finding

I examined the strongest candidate under the conservative coarse pH ranking using a more detailed molecular-mechanics calculation.

Joint refinement of the binder and human target passed independent checks on **260 alpha stereocenters, 43 beta stereocenters, bond lengths, and severe clashes**. Nevertheless, the subsequent interaction-energy diagnostic did **not** support a strong-affinity claim.

More importantly, **protonating two introduced binder histidines opposed acid-on binding in that diagnostic**, whereas protonating two contacted receptor histidines favored it. This contradicts the favorable impression created by the initial coarse ranking.

I also tested the energy subtraction with the partners separated: the interaction approached zero as expected. That checks arithmetic consistency; it does not validate affinity prediction.

**Decision: do not select this candidate merely because it leads the coarse ranking.** The next optimization needs to improve packing and exploit favorable protonation effects—not simply introduce more histidines.

## Other weaknesses caught

The independent structural screen rejected **155 candidates**, predominantly because of target-glycan clashes. Glycan exclusion therefore needs to occur during side-chain selection, rather than only afterward.

The alternative-conformation check also exposed a limitation: the current geometry survivors clash with domain I in the ligand-bound **1IVO** arrangement, although **154** remain clash-free against the unliganded **1NQL** arrangement. They are conformation-specific hypotheses, not demonstrated binders across receptor states.

Novelty screening is stronger now: the local references include **446,966 antibody sequences and 203,818 CDR3 segments**. Swiss-Prot and PDB searches also completed for every candidate. These checks still do not reproduce the organizers’ exact annotations and database snapshots, so upload acceptance remains uncertified. ([adaptyvbio.com](https://www.adaptyvbio.com/blog/novelty))

## What is preserved, and what comes next

The checkpoint contains **1,025 files**, including scientific code, the actual sequence/structure library, rejected designs, refinement results, tests, logs, and provenance manifests. All **1,022 manifested payload files** passed independent SHA-256 verification. Large original inputs and regenerable databases are referenced rather than duplicated.

The archive’s internal 366-sequence FASTA is explicitly marked **NOT FOR SUBMISSION**. The final ranked 100-sequence FASTA, public codenames, competition CSV, and top-20 subset remain pending.

The revised design direction is **acidic binder contacts to protonatable receptor histidines**, with explicit glycan exclusion and broader all-atom evaluation before ranking. The human/mouse alignment also identifies a potentially useful histidine-to-arginine substitution to investigate without incorrectly requiring mouse binding to switch with pH.

**Two Phone-a-Friend requests are used; one remains. No campaign jobs are left running.**

</details>

---

<a id="turn-10"></a>

## Turn 10 — Improve the designs — stage 3

### User

Try harder, keep making them better.

<details>
<summary>Assistant reply — expand to read</summary>

**This iteration produced a better-supported lead family—and caught a structural weakness that the earlier scores missed.** The current library contains **1,097 distinct sequences**, with substantially deeper physical evaluation of the most promising designs.

[Download the stage-3 checkpoint — 68.6 MiB](sandbox:/mnt/data/egfr_stage3_checkpoint.zip)  
[Read the detailed scientific report](sandbox:/mnt/data/egfr_stage3_report.md) · [Historical-method audit](sandbox:/mnt/data/egfr_stage3_methods_audit.md)

**This remains a checkpoint, not the final 100-sequence submission package.** Its internal FASTA is explicitly marked **NOT FOR SUBMISSION** and includes rejected designs for provenance.

## What improved

The strongest new family recognizes **protonatable histidines on EGFR**, rather than relying on adding histidines to the binder. I redesigned its surrounding contacts to remove unfavorable charges while preserving the intended acidic-pH interactions.

Crucially, the detailed calculation now distinguishes **both neutral histidine forms** from protonated histidine. This caught interfaces whose intended hydrogen bond remained available at neutral pH.

Two redesigned sequences, internally designated **C00003** and **C00009**, improved the calculated pH contrast and survived additional checks:

| Conditional model diagnostic | Parent | C00003 | C00009 |
|---|---:|---:|---:|
| Worst pH contrast across 54 histidine/salt/dielectric assumptions | 0.596 | **0.869** | **0.937** |
| Worst contrast after capping the cropped target’s artificial termini | 0.594 | **0.854** | **0.943** |
| Worst contrast across 162 assumptions including carboxylate protonation | 0.577 | **0.766** | **0.855** |

Values are in kcal/mol; positive values indicate an acid-on direction **within the model**. They are not measured binding free energies, confidence intervals, or proof of undetectable neutral-pH binding. The full calculations and assumptions are retained in the [report and checkpoint](sandbox:/mnt/data/egfr_stage3_report.md).

Both redesigns also retain favorable mouse interaction-energy diagnostics. Expanding the calculation to include four receptor histidines—including sites outside the original distance cutoff—preserves their acid-on direction. Their refined structures avoid the earlier collision with the ligand-bound **1IVO receptor conformation**, as well as the checked unliganded conformation and resolved glycans.

**The important remaining limitation:** their neutral-pH interaction scores are still favorable. Improving the contrast is not equivalent to satisfying the competition’s explicit requirement of human binding at pH 6.5 with **no detectable binding at pH 7.4**. ([proteinbase.com](https://proteinbase.com/competitions/anthropic-adaptyv-2026/challenges/egfr))

## The check that prevented premature promotion

A short, unbound molecular-dynamics trajectory of the parent revealed **substantial loop movement**: approximately **4.95 Å overall loop displacement**, including **7.25 Å in the second binding loop**, while the framework moved much less.

That is a warning about whether the designed binding surface remains properly arranged without the target. It is not erased by passing bond-length, clash, or stereochemistry checks.

The trajectory is only **10 picoseconds**, lacks thermal equilibration, and is not a folding benchmark. Nevertheless, it identifies a concrete next design problem: **stabilizing the binding-loop geometry**. C00003 and C00009 passed local unbound minimization, but they have not yet undergone equivalent dynamics checks; the parent’s movement remains a family-level risk.

## Scope of the completed checks

| Completed evaluation | Result |
|---|---:|
| Sequence/structure records | **1,114**, representing **1,097 unique sequences** |
| Detailed human all-atom/protonation evaluations | **49** |
| Acid-on direction in every one of 54 detailed-model assumptions | **27 of 49** |
| Detailed mouse evaluations | **7** |
| Full-library local CDR3 novelty screening | **All below 70%; maximum 64.71%** |
| Completed whole-sequence searches against three databases | **61 records / 60 unique sequences** |

The independent **FcRn–Fc acid-on control** gives the expected direction across all 54 assumptions. Its experimentally established pH-dependent mechanism predates the cutoff; it is used only as a control, not as a source of design sequences. ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/11336709/))

I also excluded a glycosylation-sequon-bearing variant, flagged a strained peptide bond in another candidate, and prevented unrecomputed parent scores from entering automatic ranking. The **17 duplicate sequence records** represent alternative structural hypotheses and will not count as separate submissions.

Local novelty results remain encouraging, but the organizers use their own antibody classification, numbering, and database pipeline. They are **not an upload-acceptance guarantee**. ([adaptyvbio.com](https://www.adaptyvbio.com/blog/novelty))

## Checkpoint integrity and next stage

The archive contains **4,171 files**. Independent verification matched the size and SHA-256 hash of **every one of its 4,168 manifested payload files**. It preserves code, sequences, structures, failed branches, microstate energies, controls, logs, and provenance; large original inputs are referenced rather than duplicated.

**All campaign jobs are finished. Two Phone-a-Friend requests are used; one remains.**

The next stage is targeted loop stabilization while preserving the improved pH contacts, followed by broader distinct-sequence evaluation and the final ranking. Geometrically compatible proline/glycine substitutions and additional disulfide constraints have pre-2011 precedents, but their effects must be tested here rather than assumed. ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC299143/?utm_source=chatgpt.com))

</details>

---

<a id="turn-11"></a>

## Turn 11 — Improve the designs — stage 4

### User

Try harder, keep making them better.

<details>
<summary>Assistant reply — expand to read</summary>

**I generated 63 additional designs and tested the proposed improvements against more carefully matched controls. The longer simulations overturned the apparent stabilization gains, and an added histidine worsened the conservative pH score. Those variants are not being promoted as improvements.**

This checkpoint strengthens the campaign’s evidence and eliminates misleading leads, but it does **not** establish a better experimental binder.

[Download the stage-4 checkpoint — 77.5 MiB](sandbox:/mnt/data/egfr_stage4_checkpoint.zip)  
[Detailed scientific report](sandbox:/mnt/data/egfr_stage4_report.md) · [Historical-method audit](sandbox:/mnt/data/egfr_stage4_methods_audit.md)

## The harder stability test changed the conclusion

I tested two proposed stabilizers: an additional disulfide bond and two geometry-compatible proline substitutions. Crucially, the comparison included the **unchanged parent given the same additional refinement**, so benefits from extra minimization could not be mistaken for benefits from mutations.

The short trajectories initially looked encouraging. The longer matched trajectories did not:

| Structure | Mean loop displacement over 4 ps | Mean loop displacement over 20 ps |
|---|---:|---:|
| Native nanobody control | 1.069 Å | 1.095 Å |
| Equally refined, unchanged parent | 1.395 Å | **1.732 Å** |
| Additional-disulfide variant | **1.224 Å** | 1.765 Å |
| Two-proline variant | 1.333 Å | 1.915 Å |

These are framework-aligned loop displacements, not folding energies or melting temperatures. Each duration has one trajectory per sequence; the differences do **not** establish statistical significance. Even the longer tests are extremely short, and chirality restraints remain.

**Decision:** neither mutation strategy has demonstrated stabilization in these tests. The native control also preserves its loop geometry better, reinforcing that loop preorganization remains a weakness. The trajectories, controls, analysis code, and excluded temperature-biased pilot runs are preserved in the [report and checkpoint](sandbox:/mnt/data/egfr_stage4_report.md).

## The pH problem remains the decisive obstacle

The detailed models still favor acidic-pH binding, but their neutral-pH interaction scores also remain favorable. That falls short of the actual requirement: human EGFR binding at **pH 6.5 with no detectable binding at pH 7.4**, alongside mouse binding and human affinity. A positive computed pH contrast is not sufficient. ([proteinbase.com](https://proteinbase.com/competitions/anthropic-adaptyv-2026/challenges/egfr))

I tested an additional histidine positioned near a receptor glutamate, explicitly considering both neutral histidine forms. After giving each unchanged background exactly the same additional refinement as its mutant, the minimum modeled pH contrast across the tested assumptions **decreased**:

- Uncrosslinked background: **0.782 → 0.700 kcal/mol**.
- Disulfide background: **0.745 → 0.683 kcal/mol**.

Neither is being promoted. This is another concrete reason not to treat “more histidines” as a reliable route to the required switch.

The parent and disulfide variant retain their acid-on direction after additional carboxylate-protonation and artificial-terminus checks. However, those calculations remain conditional physical models—not calibrated binding free energies or evidence of neutral-pH nondetection.

## Structural and novelty checks completed

The **63 new sequences are distinct, each 125 residues long**, and pass the initial sequence/coordinate consistency checks. They contain standard amino acids and no N-X-S/T glycosylation sequons.

Of **14 new sequences** taken through detailed human-interface calculations, **nine pass the stricter minimized-structure geometry gate**. The rejected structures include strained peptide bonds and a disulfide with an acceptable sulfur–sulfur distance but an unacceptable torsion. The equally re-refined unchanged parent also repairs the peptide-geometry problem identified in the previous checkpoint.

Three variants received detailed mouse calculations. Two pass the corresponding geometry checks and retain favorable interaction-energy diagnostics; this is **not experimental confirmation of cross-reactivity**.

All 63 completed searches against the local Swiss-Prot, PDB, and expanded antibody databases. Their maximum CDR3 edit identity against the local reference collection is **50%**, below the local screening threshold. These results do not reproduce the organizers’ exact annotation, database snapshots, and novelty pipeline, so upload acceptance remains unverified. ([adaptyvbio.com](https://www.adaptyvbio.com/blog/novelty))

## What is preserved—and the next design decision

The archive contains **4,828 files**. Independent verification matched the size and SHA-256 hash of **all 4,825 manifested payload files**. It includes code, sequences, structures, failed branches, matched controls, trajectories, tests, and provenance. Large original inputs and regenerable installations/indexes are referenced rather than duplicated.

**The internal FASTA is marked `NOT_FOR_SUBMISSION` and includes rejected variants.** The final ranked 100-sequence FASTA, public codenames, competition CSV, and top-20 subset remain pending. No modern binder generator was used; the historical-method audit records the eligible methods, modern implementations, and earlier excluded sampling provenance.

The next scientific priority is **rebuilding the problematic loop backbones and improving contacts that specifically require protonation**, rather than expanding this family through more superficially favorable point mutations. This round’s evidence argues against calling the current family “stabilized” or ready for submission.

**All campaign jobs are finished. Two Phone-a-Friend requests are used; one remains.**

</details>

---

<a id="turn-12"></a>

## Turn 12 — Improve the designs and recheck competition rules — stage 5

### User

Try harder, keep making them better. Pay attention to all the competition rules.

<details>
<summary>Assistant reply — expand to read</summary>

**Two new variants improve the conservative pH score while passing the checked human and mouse geometry gates. The improvement is modest—not evidence that they satisfy the experimental neutral-pH requirement.** This round also excluded several superficially promising designs after stronger checks.

[Download the stage-5 checkpoint — 99.7 MiB](sandbox:/mnt/data/egfr_stage5_checkpoint.zip)  
[Detailed scientific report](sandbox:/mnt/data/egfr_stage5_report.md) · [Historical-method audit](sandbox:/mnt/data/egfr_stage5_methods_audit.md)

## What improved

I generated **276 new, distinct sequences** through backbone rebuilding and targeted changes to the proposed pH-sensitive contacts. The backbone search made **13,439 attempts**, retaining **94 geometries**.

The most useful change came from checking the actual interface rather than continuing to optimize the earlier contact assumptions. That audit identified an additional glutamate contact that the earlier protonation analysis had omitted. I expanded the calculation to include it—and every newly introduced nearby acidic group.

The surviving improvements are **H00011** and **H00021**, compared below with their equally refined, unchanged parent:

| Conditional model diagnostic | Matched parent | H00011 | H00021 |
|---|---:|---:|---:|
| Minimum pH contrast with independent histidine assumptions | 0.772 | **0.931** | **0.845** |
| Minimum contrast after expanding to the engineered acidic groups | 0.601 | **0.697** | **0.665** |
| Checked human geometry | Pass | Pass | Pass |
| Checked mouse geometry | Pass | Pass | Pass |

Contrasts are in **kcal/mol within the model**; positive means an acid-on direction. They are not measured binding free energies, confidence intervals, or calibrated affinities. H00011’s expanded calculation included **729 protonation/tautomer states and 39,366 combinations of assumed parameters**. Those combinations test sensitivity to assumptions; they are not independent experimental validations. [The complete comparisons and limitations are preserved here.](sandbox:/mnt/data/egfr_stage5_report.md)

**A third variant, H00020, had a favorable pH score but failed the stricter mouse peptide-geometry check.** Its peptide bond deviated 26.30° from trans, beyond the predeclared 25° limit. I retained the failure rather than relaxing the threshold.

## What did not improve

**Shortening the loops did not establish stabilization.** I completed two predeclared, matched-seed trajectories for each shortened design, the unchanged parent, and a native control:

| Structure | Mean loop displacement across the two trajectories |
|---|---:|
| Native control | 1.283 Å |
| Unchanged parent | 1.872 Å |
| Shortened-loop design N2070600 | 2.052 Å |
| Shortened-loop design N2091100 | 1.867 Å |

The apparent advantage of the second shortened design is negligible, and its two trajectories differ substantially. It also clashes with more of the tested glycan arrangements than the parent. Neither shortened design is being called stabilized.

These are **20-picosecond production trajectories**, not folding studies. The new H00011/H00021 variants received matched unbound minimization checks, which passed, but **have not yet received equivalent thermal tests**. The report keeps these evidence levels separate. [Trajectory results and glycan checks](sandbox:/mnt/data/egfr_stage5_report.md)

## Rules and screening

All **276 sequences** completed searches against the local Swiss-Prot, PDB, and expanded antibody databases. One sequence, **N3081002**, reached **71.43% local CDR3 edit identity** and is excluded. In total, **230** pass both the initial sequence/geometry checks and the local CDR3 novelty screen; that is not a count of validated binders.

Common antibody frameworks are evaluated differently from general proteins in Proteinbase’s novelty scheme. I am **not** claiming that these designs all qualify as wholly novel frameworks, nor that local screening reproduces the organizers’ classifier and database snapshots. ([adaptyvbio.com](https://www.adaptyvbio.com/blog/novelty))

The submission constraints remain explicit: **Track 3 permits at most 20 designs**, so the requested 100 must be a reserve pool. The official upload is a ranked CSV; the requested FASTA is an additional deliverable. Human binding at pH 6.5 with **no detectable binding at pH 7.4** remains the decisive requirement. Mouse binding is required, but mouse pH switching is not. The deadline is **October 4, 2026, 23:59 AoE—October 5 at 6:59 a.m. Chicago time**. ([proteinbase.com](https://proteinbase.com/competitions/anthropic-adaptyv-2026/challenges/egfr))

**The current neutral-pH interaction proxies remain favorable. Consequently, I have not marked any design as passing all three biological criteria.**

## Checkpoint integrity and remaining work

The archive contains **6,243 files**. Independent verification matched the size and SHA-256 hash of **all 6,240 manifested payload files**. It preserves code, sequences, coordinates, trajectories, protonation-state calculations, rejected designs, logs, and provenance. [Verification record](sandbox:/mnt/data/egfr_stage5_verification.json)

This round used historical scientific methods with the permitted modern implementations. No modern protein generator or learned predictor was run; the earlier excluded PCG64 pilot remains documented rather than hidden.

**The internal 276-sequence FASTA is marked `NOT_FOR_SUBMISSION` and includes rejected designs.** The final ranked 100, public codenames, official CSV, and top-20 subset remain pending. The next comparison must place the surviving variants and earlier leads under the same expanded checks before declaring a campaign-wide ranking.

**All campaign jobs are finished. Two Phone-a-Friend requests are used; one remains.**

</details>

---

<a id="turn-13"></a>

## Turn 13 — Updated novelty guidance and request to continue

### User

There is new information about protein novelty assessment. Use that [https://www.adaptyvbio.com/blog/novelty](https://www.adaptyvbio.com/blog/novelty). Adaptyv will also running these novelty assessments for us during submission. Keep going.

<details>
<summary>Assistant reply — expand to read</summary>

## Completed: 100 ranked candidate sequences

**[Download the ranked 100-sequence FASTA](sandbox:/mnt/data/egfr_ranked_100.fasta)**  
**[Download the Track 3 top-20 submission CSV](sandbox:/mnt/data/egfr_track3_top20.csv)**  
[Download the submission-file bundle](sandbox:/mnt/data/egfr_submission_files.zip)

The FASTA contains **100 unique sequences**, **119–127 residues long**, with opaque biochemical-pun codenames. The CSV contains the first 20 in the same order, using exactly `name,sequence,molecule_class`.

**Use the top-20 CSV for the initial submission.** Track 3 permits at most 20 designs; the remaining sequences are reserves for replacements after Adaptyv’s assessment. The bundle includes an offline formatter that can exclude rejected names while preserving rank order. It does not perform or bypass novelty screening. ([proteinbase.com](https://proteinbase.com/competitions/anthropic-adaptyv-2026/challenges/egfr))

**These are ranked experimental candidates—not confirmed binders. Human acidic binding, neutral-pH nondetection, mouse binding, affinity, and expression remain experimentally unverified.**

## How the updated novelty policy changed the selection

I applied the **antibody-specific interpretation**, rather than rejecting these intended nanobodies merely because their frameworks resemble known proteins. The updated policy distinguishes **novel CDRH3s on familiar frameworks—level 3—from level 4**, which additionally requires lower global sequence similarity. Preserving a familiar framework is therefore not automatically disqualifying under that scale. ([adaptyvbio.com](https://www.adaptyvbio.com/blog/novelty))

Across the final 100, the highest **local CDRH3 edit identity is 55.56%**, below the local 70% safeguard. Every final sequence has completed searches against Swiss-Prot, PDB sequences, and the augmented antibody collection, with query reconciliation and exact-reference controls.

Those are safeguards, **not official novelty scores**. Adaptyv’s classification, CDR annotation, database snapshots, and submission assessment remain authoritative. I did not run its modern classification or structure-prediction pipeline locally.

## What improved in the final round

This round added **16 new sequence combinations**, alongside **five unchanged-sequence controls constructed on the same backbone**. It also completed alternative-pose comparisons and missing mouse evaluations: **68 detailed human/mouse models**, of which **59 passed the combined geometry and receptor-context gate**.

The leading combined-contact designs reached approximately **0.81 kcal/mol of conservative modeled pH contrast**, compared with **0.60 kcal/mol for the matched unchanged parent**. These calculations include the introduced acidic groups, independent protonation assumptions, and held-out checks of the classical energy approximation. The two leading values are effectively tied at the precision justified by the model.

**That improvement does not establish the required pH switch.** The neutral-pH interaction proxies remain favorable. They cannot be interpreted as evidence of *no detectable binding at pH 7.4*, and I have not converted them into invented affinities or binding ratios.

The final panel preserves the distinction between evidence levels:

| Evidence available | Candidates in the full 100 |
|---|---:|
| Human/mouse all-atom geometry checks plus expanded acid/histidine analysis | **11** |
| Human/mouse all-atom geometry checks plus narrower histidine analysis | **14** |
| Detailed human analysis; mouse geometric prefilter only | **3** |
| Exploratory reserves with coarse modeling and initial geometry checks | **72** |

**All top-20 entries come from the first two rows:** 11 with expanded protonation analysis and nine with the narrower analysis. The exploratory reserves are not presented as equally well supported. The panel contains **85 distinct designed CDRH3 sequences**, with no CDRH3 represented more than six times.

The [scientific report](sandbox:/mnt/data/egfr_campaign_report.md) records the comparisons, exclusions, assumptions, and remaining folding/preorganization risks.

## Validation and historical-method certification

Independent release checks passed **237 tests**, including sequence identity checks against **61 actual coordinate models**, FASTA/CSV order agreement, source hashes, explicit screening coverage, and reproducible selection. The numerical suite separately passed **148 implementation checks**. These are implementation and consistency checks—not biological validation.

**For the delivered sequences’ accepted lineage, I certify that the scientific method classes used date to 2010 or earlier**, with the modern implementations and datasets you expressly permitted. No modern protein-binder generator or learned protein predictor was run.

There is an explicit historical exception: an early, discarded **PCG64 pilot** fell outside the cutoff. The final 100 all trace to the regenerated **MT19937 lineage**, but I cannot truthfully certify that every exploratory operation in the entire campaign history complied. The [methods certificate](sandbox:/mnt/data/egfr_methods_certificate.md) preserves that distinction.

## Campaign records

[Download the complete campaign checkpoint — approximately 136 MiB](sandbox:/mnt/data/egfr_campaign_final_checkpoint.zip)

It contains the preserved scientific code, sequences, structures, calculations, rejected branches, controls, logs, and provenance. Large original input archives and regenerable installations/indexes are referenced rather than duplicated. **All 7,737 manifested payload files passed independent SHA-256 and size verification.**

The [private codebook and evidence table](sandbox:/mnt/data/egfr_private_codebook.tsv), [release validation](sandbox:/mnt/data/egfr_release_validation.json), and [archive verification](sandbox:/mnt/data/egfr_campaign_final_verification.json) are also available separately. The public submission CSV contains none of the internal design identifiers or methodology.

**Two Phone-a-Friend requests were used; one remains unused. No campaign jobs are left running.**

</details>

---

<a id="turn-14"></a>

## Turn 14 — Improve the completed panel

### User

Make them even better.

<details>
<summary>Assistant reply — expand to read</summary>

## Revised 100-sequence panel

**[Download the revised ranked FASTA](sandbox:/mnt/data/egfr_ranked_100_v2.fasta)**  
**[Download the Track 3 top-20 CSV](sandbox:/mnt/data/egfr_track3_top20_v2.csv)**  
[Download the submission-file bundle](sandbox:/mnt/data/egfr_submission_files_v2.zip)

**Nine new candidates replace nine lightly evaluated reserves. The top 20 remain unchanged.** The replacements have substantially more computational characterization, but none demonstrated a sufficiently clear overall advantage to displace the leading submissions.

This round generated **22 new sequences**, completed **23 human and 10 mouse all-atom models**, and tested the principal variants against an unchanged parent and a native control. The [scientific report](sandbox:/mnt/data/egfr_revision_v2_report.md) preserves the favorable results, contrary results, and selection decisions.

## What changed in the sequences

I targeted the persistent loop-flexibility problem through selected **glycine-to-alanine or glycine-to-serine substitutions**, while preserving the framework and proposed pH-contact residues. Glycines needed for positive backbone angles were retained. Geometry-compatible glycine replacement has an experimental precedent before 2011, but that precedent does not establish that these particular substitutions improve stability. ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC299143/))

All 22 new sequences are **125 residues long**. The nine retained replacements occupy **ranks 21–29** in the revised FASTA, with codenames such as `SilentCatalyst_Umbra` and `BondVoyage_Cipher`.

### The strongest results—and their tradeoff

The two principal variants reduced average loop movement in both short simulations. Their conservative modeled pH contrast, however, decreased slightly.

| Candidate | Mean loop displacement, run 1 | Mean loop displacement, run 2 | Conservative modeled pH contrast |
|---|---:|---:|---:|
| Matched unchanged parent | 2.126 Å | 1.869 Å | 0.799 kcal/mol |
| `BondVoyage_Cipher` | **1.734 Å** | **1.799 Å** | 0.762 kcal/mol |
| `SilentCatalyst_Umbra` | **1.762 Å** | **1.743 Å** | 0.780 kcal/mol |

Lower displacement is favorable for this particular geometry-retention diagnostic. Higher positive pH contrast favors acidic binding **within the conditional model**. Neither column establishes experimental stability, affinity, or neutral-pH nondetection. [Complete comparisons and assumptions](sandbox:/mnt/data/egfr_revision_v2_report.md)

Before seeing the complete results, I required at least **0.15 Å less mean loop movement in each run**, without worsening late-trajectory movement. Neither variant met that rule: the second-run improvements were approximately **0.070 Å** and **0.126 Å**. I did not lower the threshold afterward.

A secondary diagnostic was encouraging: backbone movement at the intended pH-contact positions decreased by approximately **0.47–0.58 Å** in both runs. That remains a descriptive finding, not a substitute for the failed primary promotion rule.

These were only **20-picosecond production trajectories**, not equilibrium folding studies. The variants also rearranged more than the parent during unbound minimization. That warning remains part of their evidence.

## Stronger checks, not just more favorable scores

I identified and removed a potential bias: replacing glycine creates additional stereocenters, which acquired extra chirality restraints under the inherited simulation protocol. The primary comparisons therefore used **no added chirality restraints**, so artificial stiffening could not masquerade as a mutation benefit.

All **33 newly refined human/mouse models** passed the strict minimized-geometry and checked receptor-context gates. Separate thermal endpoint checks were less uniformly favorable: after identical endpoint minimization, **9 of 12** passed the strict gate; three native-control endpoints retained peptide-angle warnings. Those failures remain documented rather than being hidden or used to claim that the native protein cannot fold. [Structural and thermal audit](sandbox:/mnt/data/egfr_revision_v2_report.md)

The revised panel now has:

| Computational evidence available | Previous panel | Revised panel |
|---|---:|---:|
| Expanded protonation analysis and both-species geometry checks | 11 | **13** |
| Narrower protonation analysis and both-species geometry checks | 14 | **21** |
| Detailed human analysis with more limited mouse checks | 3 | 3 |
| Exploratory reserves with coarse modeling | 72 | **63** |

Thus, **34 candidates now have detailed human and mouse structural checks**, compared with 25 previously. This is improved evidence coverage—not a count of confirmed cross-reactive binders.

## Novelty and submission rules

The revised FASTA contains **100 unique sequences**, **119–127 residues long**, and **84 distinct designed CDRH3 sequences**. All 22 new sequences completed the three local database searches. Their maximum local CDRH3 edit identity is **50%**; the maximum across the final 100 is **55.56%**.

Those local results do not establish official novelty or antibody classification. Adaptyv’s antibody-specific assessment uses its own classification, annotation, and database pipeline; conserved framework similarity is not by itself an automatic rejection under that scheme. ([adaptyvbio.com](https://www.adaptyvbio.com/blog/novelty))

**The top-20 CSV contains exactly the same names, sequences, and order as the previous top-20 CSV.** There is no reason to replace an already uploaded set merely because the filename now says `v2`. The revised FASTA supplies better-characterized reserves if replacements are needed. Track 3 still permits **at most 20 designs**, not 100. ([proteinbase.com](https://proteinbase.com/competitions/anthropic-adaptyv-2026/challenges/egfr))

The extended deadline is **October 6, 2026, at 23:59 AoE—October 7 at 6:59 a.m. Chicago time**. The biological requirement remains human binding at pH 6.5 with no detectable binding at pH 7.4, alongside mouse binding and human affinity. **None of those experimental outcomes is yet established for these candidates.** ([proteinbase.com](https://proteinbase.com/competitions/anthropic-adaptyv-2026/challenges/egfr))

## Certification and preserved campaign

**For this revision and the accepted lineage of the delivered sequences, I certify that the scientific method classes used date to 2010 or earlier**, with the modern implementations and datasets you permitted. No modern protein-binder generator or learned structure/interaction predictor was run. The previously disclosed, excluded PCG64 pilot remains recorded; the certificate does not falsely claim that every historical exploratory operation complied.

[Historical-method certificate](sandbox:/mnt/data/egfr_methods_certificate_v2.md) · [Private codebook and evidence](sandbox:/mnt/data/egfr_private_codebook_v2.tsv)

**[Download the complete updated campaign checkpoint — 156.7 MiB](sandbox:/mnt/data/egfr_campaign_v2_checkpoint.zip)**

The archive contains the previous scientific record plus this revision’s code, sequences, structures, trajectories, calculations, controls, failures, and provenance. Large original inputs and regenerable installations/indexes are referenced separately. All **8,417 manifested payloads** passed independent size and SHA-256 verification; all **7,737 previously manifested payloads remain unchanged**.

[Release validation: 1,022 checks passed](sandbox:/mnt/data/egfr_release_validation_v2.json) · [Archive verification](sandbox:/mnt/data/egfr_campaign_v2_verification.json)

**All campaign jobs are finished. Two Phone-a-Friend requests were used; one remains unused.**

</details>

---

<a id="turn-15"></a>

## Turn 15 — Campaign completion status

### User

Is the campaign done?

<details>
<summary>Assistant reply — expand to read</summary>

**The computational design-and-delivery phase is done. Submission and biological validation are not.** Version 2 is the completed release—not a job still running in the background.

| Campaign component | Status |
|---|---|
| Generate and rank 100 distinct candidate sequences | **Complete** |
| Prepare the top-20 submission CSV and reserve pool | **Complete** |
| Preserve code, calculations, controls, failures, and provenance | **Complete**, with the disclosed historical-method exception |
| Obtain Adaptyv’s official novelty and eligibility assessment | **Pending** |
| Demonstrate the three biological objectives experimentally | **Not established** |

The current deliverables are the **[ranked 100-sequence FASTA](sandbox:/mnt/data/egfr_ranked_100_v2.fasta)**, **[top-20 submission CSV](sandbox:/mnt/data/egfr_track3_top20_v2.csv)**, and **[complete campaign archive](sandbox:/mnt/data/egfr_campaign_v2_checkpoint.zip)**.

### The distinction that matters

We have produced **computationally prioritized experimental candidates**, not demonstrated winners. The most important unresolved weakness is that the models still permit favorable **neutral-pH binding**. Therefore, they do not establish the required acidic-pH selectivity. Mouse binding, human affinity, folding, and expression also remain experimentally unverified.

The latest revision improved the characterization of nine reserves, but **did not produce sufficient evidence to change the top 20**. Its leading mutations showed some favorable loop-motion diagnostics while slightly worsening the conservative modeled pH contrast. Those tradeoffs and the failed promotion criteria are recorded in the [revision report](sandbox:/mnt/data/egfr_revision_v2_report.md).

### Where I would stop

**I would freeze v2 for the submission handoff.** Further computation could explore new hypotheses, but another round of small changes under the same uncalibrated scoring model would not, by itself, resolve the central biological uncertainty. Calling that continued activity “progress” without stronger evidence would be misleading.

I have not submitted any sequences. The next consequential step is the organizer’s assessment of the top-20 set, followed by experimental testing; the reserve pool is available for rejected entries.

**So: the requested design package is finished. The original ambition—to satisfy all three criteria and win—has not been demonstrated, and I cannot honestly call that objective achieved.**

</details>

---

<a id="turn-16"></a>

## Turn 16 — Plan public repository contents

### User

I want to share as many intermediate campaign files as possible in a GitHub repo. However, the unzipped archive is far too large. What files should be tracked and which should be ignored?

<details>
<summary>Assistant reply — expand to read</summary>

**Keep the inspectable scientific record in Git, and publish the complete checkpoint as a GitHub Release asset.** That lets you share essentially the whole campaign without making every clone contain every intermediate coordinate file.

**Do not blanket-ignore `intermediate/`, `*.json`, `*.pdb`, `*.npz`, or `*.log`.** Those contain substantial scientific evidence—including failed designs, controls, and the calculations behind the rankings.

I inspected the actual archive and prepared a file-by-file selection.

## Recommended repository size

| Item | Files | Size |
|---|---:|---:|
| Full expanded v2 checkpoint | 8,419 | **567.6 MiB** |
| Original campaign files recommended for Git | **5,532** | **233.1 MiB** |
| Additional scientific files retained in the downloadable checkpoint | 2,818 | 334.0 MiB |
| Paper-page images held for publication review | 2 | 0.48 MiB |
| Disposable process-ID files | 67 | Negligible |

I also tested the selected files in a fresh local Git repository. **After packing, its Git objects occupied 56.22 MiB**, including the generated inventories and validation records. That is a measurement of this initial snapshot, not a guarantee about future repository growth. [Storage measurement](sandbox:/mnt/data/egfr_repository_storage_measurement.json)

The largest individual original file is only **20.86 MiB**. None of the expanded files hits GitHub’s regular-Git warning threshold of 50 MiB or blocking threshold of 100 MiB. The **156.7 MiB checkpoint ZIP itself**, however, should be a Release attachment—not a regular Git blob. ~~~~~~~~~~~~~~~~~~~~~~~~

## What to track

The following policy preserves the existing directory structure and original file contents.

| Category | What to retain in Git |
|---|---|
| **All scientific code** | Every original Python and shell file, including helper scripts, tests, failed implementations, and superseded versions. The checkpoint contains **268 Python files and three shell files**. |
| **Reports and methodology** | Current and historical reports, method certificates, strategy records, restoration instructions, environment records, and descriptions of limitations. Keep the disclosed historical-method exception. |
| **Provenance and manifests** | Input sources, download metadata, checksums, seeds, candidate ancestry, task records, and all original included/excluded-file manifests. |
| **Candidate results—including failures** | Evaluation records, geometry audits, clash checks, novelty outcomes, pH calculations, model-sensitivity results, and rejection reasons. Keep the **234 search-summary records** located alongside the larger design files. |
| **Search evidence** | Candidate/query FASTAs, observed BLAST result tables, local novelty results, and control-search results. These are distinct from the large reference databases and their indexes. |
| **Saved numerical arrays** | All **78 `.npz` and three `.npy` files** currently in the checkpoint. These include trajectory traces and energy tensors; they are scientific results, not merely software caches. |
| **Selected coordinate evidence** | Exact design records for the final 100 and selected matched parents; **81 selected refined models**; and control, unbound, protonation-analysis, and trajectory-endpoint structures outside the bulk refinement directories. This retains **224 PDB files altogether**. |
| **Observed logs and releases** | All **588 `.log` files**, final and historical sequence panels, submission-format files, validation results, and the name-to-design codebook. |

These choices are recorded for every archive member in the [complete inventory](sandbox:/mnt/data/egfr_repository_inventory.json).

**Keep failures and controls, not just attractive final structures.** Otherwise, readers would see the claimed improvements without the evidence that overturned earlier claims.

## What to ignore in Git—but preserve elsewhere

### Additional coordinate-heavy scientific files: put them in the Release asset

The proposed selection moves **1,787 other coordinate-bearing design JSON files** and **1,031 additional PDB files** out of Git tracking.

That includes nonselected designs, additional refinement poses, repeated partner structures, initial structures, and alternative protonation-coordinate files. Their **scores, audits, summaries, and provenance remain tracked**. Their complete original coordinates remain available in the full checkpoint.

These files are **not necessarily disposable or exactly reproducible**. In particular, rerunning a calculation is not an adequate substitute for preserving its actual saved output. “Release-only” means a different storage location, not permission to delete the scientific record.

Attach the checkpoint explicitly to a release such as `campaign-v2`. GitHub’s automatically generated “Source code” ZIP will contain the Git-tracked selection, **not** the separately attached full checkpoint. GitHub Releases support downloadable assets, and this checkpoint is comfortably below their documented per-asset limit. ~~~~~~~~~~~~~~~~~~~~~~

### Downloaded inputs and regenerated infrastructure: keep outside Git

Do not commit the large original input archives, downloaded database snapshots, unpacked software, installed environments, or generated BLAST indexes. Keep their source addresses, versions, checksums, acquisition scripts, and restoration instructions instead.

In this campaign, that includes `resources.zip`, `egfr_inputs.zip`, and `egfr_refinement_inputs.zip`, plus their unpacked bulk payloads. Preserve exact input snapshots in appropriate external storage when redistribution terms permit; a downloader pointing at a changing “current release” is not a substitute for identifying the original snapshot.

Likewise, do not commit each cumulative checkpoint ZIP. Preserve the historical code and results already included in v2, rather than nesting multiple copies of the campaign inside Git history.

### Actual disposable files: ignore normally

Interpreter/JIT caches, installed environments, temporary files, editor files, and stale `.pid` files can be ignored. **Logs are different:** the saved campaign logs are small and useful, so the supplied policy keeps them.

## Ready-to-use files

**[Download the GitHub publication kit — approximately 508 KiB](sandbox:/mnt/data/egfr_github_publication_kit.zip)**

It contains the exporter, a tailored `.gitignore`, `.gitattributes`, the complete inventory, exact tracked/release-only path lists, and validation results. It does **not** duplicate the scientific dataset.

The simplest route is to download **[prepare_egfr_repository.py](sandbox:/mnt/data/prepare_egfr_repository.py)**, place it beside the original checkpoint, and run:

```bash
python prepare_egfr_repository.py egfr_campaign_v2_checkpoint.zip egfr-public
```

This creates a **new directory** containing the selected files and publication metadata. It uses only Python’s standard library and:

- Verifies the checkpoint’s pinned SHA-256 and all **8,417 original manifested payloads**.
- Copies selected files **byte-for-byte**, without altering the original archive.
- Refuses to overwrite an existing destination; it does not install software, run scientific calculations, initialize Git, or upload anything.

The exporter was tested against the actual archive. I also checked the ignore rules with Git against **every archive path**, confirming that they exclude the intended files without hiding any selected payload.

For inspection without extracting the scientific files:

```bash
python prepare_egfr_repository.py egfr_campaign_v2_checkpoint.zip egfr-plan --plan-only
```

Standalone files are also available:

[Recommended `.gitignore`](sandbox:/mnt/data/egfr_recommended.gitignore) · [Recommended `.gitattributes`](sandbox:/mnt/data/egfr_recommended.gitattributes) · [Detailed policy guide](sandbox:/mnt/data/egfr_repository_policy.md)

**The `.gitignore` belongs in the directory containing `egfr_campaign/`.** Its omissions are exact paths for this checkpoint, rather than broad exclusions that could conceal useful future results. The `.gitattributes` preserves the historical files’ bytes across platforms, avoiding inadvertent line-ending changes to checksummed files.

## Important publication cautions

**The light checkout is not a complete execution environment.** Some historical scripts require the omitted data, the original input archives, and the original `/mnt/data/egfr_campaign` layout. Keep the restoration instructions and explain this boundary in the README. The original manifests will intentionally reference files absent from the light checkout; do not rewrite them to conceal those omissions.

**Review the full Release attachment as well as the Git tree.** I withheld two paper-page images from the proposed Git selection pending a permissions review, but they remain inside the original checkpoint. Database-derived reference material also warrants a terms review. This storage audit was not a comprehensive licensing or secret scan. Choose an explicit license for your original code and documentation, while treating third-party material separately. ([docs.github.com](https://docs.github.com/en/repositories/managing-your-repositorys-settings-and-features/customizing-your-repository/licensing-a-repository))

**The codebook is intentionally included.** It makes the science easier to follow, but it reveals the connection between public codenames and internal designs. Publishing the source, reports, and codebook is incompatible with continuing to obscure the design process through those names.

**A `.gitignore` does not shrink existing history.** It also does not remove files from your current disk. Use the exporter to create a smaller working tree. Files already tracked remain tracked until explicitly removed from the index, and earlier committed versions remain in history. A fresh export is the cleanest starting point for a new public repository. ([git-scm.com](https://git-scm.com/docs/gitignore))

I would **not introduce Git LFS for this frozen campaign by default**. LFS stores pointers in Git and the actual payloads separately; it is useful when large files need ongoing versioning. Here, ordinary Git for the selected evidence plus an immutable Release attachment for the full checkpoint is simpler. ([docs.github.com](https://docs.github.com/repositories/working-with-files/managing-large-files/about-git-large-file-storage?utm_source=chatgpt.com))

**Bottom line: track the 5,532-file evidence-rich selection, publish the remaining scientific payloads through a reviewed Release asset, and discard only genuinely disposable runtime clutter.**

</details>

---

<a id="turn-17"></a>

## Turn 17 — Novelty checks passed; request a short strategy and methods outline

### User

I'll work on that.

Here is the output novelty check. All 20 passed.

I also want a quick outline of the design strategy and methods used along with date assurances. This is only a few sentences.

> **Upload metadata:** `novelty-check.txt`. File contents are not embedded in this log.

<details>
<summary>Assistant reply — expand to read</summary>

**All 20 passed the reported novelty assessment: 12 scored 3/4 and eight scored 4/4**—this establishes the novelty result, not experimental binding or pH selectivity. fileciteturn2file0L1-L40

The campaign retained a generic nanobody framework but rebuilt all three binding loops de novo, targeting conserved human/mouse EGFR surfaces and protonation-dependent contacts intended to favor human binding at pH 6.5 over 7.4. Classical loop construction, docking and side-chain packing were followed by **Amber99SB (2006)/OBC implicit-solvent (2004)** refinement, explicit protonation-state comparisons, short molecular-dynamics checks and BLAST-based sequence screening. The [method audit](sandbox:/mnt/data/egfr_methods_certificate_v2.md) certifies that the **accepted final-design lineage uses scientific methods established by 2010**, with modern implementations and datasets as expressly permitted; no modern protein-binder generator or learned sequence, structure or interaction predictor was run. An early noncompliant random-number-generator pilot was discarded and replaced with **MT19937 (1998)**, so that assurance applies to the delivered designs’ accepted lineage, not every exploratory operation in the campaign’s history.

</details>

---

<a id="turn-18"></a>

## Turn 18 — Adapt the publication plan to the existing repository

### User

We need to reorganize the plan to prepare the public repo. I have subdirectories already established. gpt6 contains all outputs, including the unzipped archive from before. I have an initial .gitignore. We need to expand on that, not start over.

> **Upload metadata:** `repo-content.txt`, `.gitignore(1)`. File contents are not embedded in this log.

<details>
<summary>Assistant reply — expand to read</summary>

**Keep your existing repository and directory structure. The change should be an append-only update to the root `.gitignore`, not a new export or a reorganization of the files.**

I prepared that update. It preserves your existing five exclusions—including the input archives and download directories—and adds the campaign-specific rules under **`/gpt6/` only**. Your original `.gitignore` content is retained byte-for-byte. fileciteturn4file1L1-L6

**[Download the in-place repository update kit](sandbox:/mnt/data/egfr_existing_repo_update.zip)**

## Apply it to the existing repository

Save these two files together in your existing `gpt6/` directory:

[Update script](sandbox:/mnt/data/update_egfr_gitignore.py) · [Rules to append](sandbox:/mnt/data/egfr_gitignore_additions.txt)

From the **repository root**, run:

```bash
python gpt6/update_egfr_gitignore.py
```

That previews the change without modifying anything. Then apply it and inspect the diff:

```bash
python gpt6/update_egfr_gitignore.py --apply
git diff -- .gitignore
```

The updater appends the rules to your **actual current file**, so it also preserves any edits you have made since uploading it. It saves a byte-exact backup in Git’s metadata directory, detects an already-applied update, and **does not move, delete, stage, or untrack any campaign files**.

There is also a **[complete merged `.gitignore` preview](sandbox:/mnt/data/egfr_root.gitignore)** based on the version you uploaded. Prefer the updater over copying that preview onto a file you have edited subsequently.

**Do not run the earlier `prepare_egfr_repository.py` exporter for this plan.**

## What changes—and what stays where it is

The earlier file selection is now mapped to `gpt6/egfr_campaign/...`, rather than assuming `egfr_campaign/...` sits at the repository root.

| Location or category | Updated treatment |
|---|---|
| `gpt6/egfr_campaign/` scientific record | Keep the same **5,532 selected files**, approximately **233.1 MiB** before Git compression. |
| Additional coordinate-heavy intermediates | Ignore **2,818 exact paths** in Git; retain their complete contents in the checkpoint/Release attachment. |
| Stale process identifiers and paper-page images | Ignore 67 `.pid` files and retain the previous publication-review hold on two paper images. |
| `gpt6/` input downloads, installed software, caches, and ZIP bundles | Preserve your existing exclusions and add scoped protection for restored or newly generated bulk files. |
| Root documents, `resources/`, and other project directories | **No additional exclusions or structural changes.** |

Your root `README.md`, `LICENSE`, and `novelty-check.txt` stay in place, as does `gpt6/prompt.txt`. The convenience copies of the final outputs under `gpt6/` remain visible too. Those are already part of your established layout. fileciteturn6file1L19-L28 fileciteturn6file0L8-L9

The long exact-path section is intentional. It avoids blanket exclusions such as `intermediate/`, `*.json`, `*.pdb`, `*.npz`, or `*.log`, which would hide useful results and controls. New scientific files with previously unseen names remain visible for review.

I tested the rules using real Git against **all 8,544 non-Git leaf paths in your listing**, including every one of the **8,419 checkpoint paths**. All **39 checks passed**, including preservation of the selected files, existing exclusions, other directories, and the updater’s unchanged-index behavior. This verifies the path policy—not the contents or tracked status of files on your computer. [Validation results](sandbox:/mnt/data/egfr_repo_inplace_update/validation.json)

## Check already-tracked files separately

**Your directory listing does not tell me which files are already tracked.** A `.gitignore` update does not stop tracking files that are already in the index. ([git-scm.com](https://git-scm.com/docs/gitignore))

After applying the update, run this read-only check:

```bash
git ls-files -ci --exclude-standard -- gpt6 resources/resources.zip
```

It lists tracked files in those locations that also match ignore rules. No output means there are no such matches in that scope. ([git-scm.com](https://git-scm.com/docs/git-ls-files))

For any listed file you have reviewed and decided to untrack, use:

```bash
git rm --cached -- "path/to/the-reviewed-file"
```

`--cached` removes the file from Git’s index while preserving your local copy. Do not add `--force` to bypass a safety error. **Do not use `git rm -r --cached .` or clear the whole repository’s index.** ([git-scm.com](https://git-scm.com/docs/git-rm))

You can preview the subsequent staging operation without staging anything:

```bash
git add --dry-run -- .gitignore gpt6 novelty-check.txt
```

## Preserve the historical file bytes

For the checksummed campaign files, append this narrowly scoped rule to the root `.gitattributes`, preserving any existing contents:

```gitattributes
gpt6/egfr_campaign/** -text
```

This disables Git’s line-ending normalization for the historical campaign without changing other directories. It does not repair normalization that may already have occurred. The kit includes this as a separate additions file; the `.gitignore` updater does not modify attributes automatically. ([git-scm.com](https://git-scm.com/docs/gitattributes))

The storage plan otherwise remains unchanged: **keep selected evidence in Git and attach the reviewed full checkpoint separately to a GitHub Release**. That attachment is distinct from GitHub’s automatically generated source archive. ([docs.github.com](https://docs.github.com/en/repositories/releasing-projects-on-github/about-releases))

**This supersedes the fresh-export workflow only. Your repository, directory names, existing documentation, and original campaign files stay intact.**

</details>

---

<a id="turn-19"></a>

## Turn 19 — Request only the gitignore file

### User

You are overcomplicating this. I do not want to add a dozen new files. Provide only the .gitignore file and use my existing paths to keep or ignore files. You have all of them.

<details>
<summary>Assistant reply — expand to read</summary>

[Download .gitignore](sandbox:/mnt/data/.gitignore)

</details>

---

<a id="turn-20"></a>

## Turn 20 — Git add appears to hang; ask the new-file count

### User

```bash
git add .
```

is now hanging. How many new files are added?

> **Response-status note:** The available conversation shows “Stopped thinking”; no completed assistant reply is present before the next user message.

---

<a id="turn-21"></a>

## Turn 21 — Verify the staged files and ignore patterns

### User

Are these the correct added files? Did the ignore patterns work?

> **Upload metadata:** `added-files.txt`. File contents are not embedded in this log.

<details>
<summary>Assistant reply — expand to read</summary>

**Yes—the staged campaign files exactly match the intended selection, and the ignore patterns worked.**

Your status contains **5,532 new files** plus **one modified `.gitignore`**, for **5,533 staged changes total**. fileciteturn11file0L1-L5 fileciteturn11file1L6-L10

I compared every staged path against the publication inventory and tested the supplied `.gitignore` using Git against all **8,419 campaign paths**:

| Check | Result |
|---|---:|
| Intended campaign files staged | **5,532 / 5,532** |
| Intended files missing | **0** |
| Unexpected files staged | **0** |
| Excluded campaign files correctly ignored | **2,887 / 2,887** |

The retained campaign files represent approximately **233.1 MiB uncompressed**. The large downloads, ZIP archives, and excluded intermediate files are not among the staged additions.

**`added-files.txt` itself is untracked**, so it is not currently included in the pending commit. fileciteturn10file0L44-L46

**No corrective changes are needed to this staged selection.** This verifies the newly staged files shown in your output, not files committed previously.

</details>

---

<a id="turn-22"></a>

## Turn 22 — Request this conversation export

### User

Export a markdown formatted log of this entire conversation to track the prompts I provided.

> **Response-status note:** Export boundary: this is the request that produced this Markdown log. The export-generation messages and delivery reply are not included recursively.

---
